Improving cancer communication in Rwanda
Official title: Validation of Quality Measures for Patient-Centered Cancer Communication in Rwanda
Funded at University of California, San Francisco · NIH-11034097 · Data updated 2026-11-12
This study is all about making conversations between cancer patients and their doctors better in Rwanda, so patients can feel more supported and involved in their care, which can help them stick to their treatment and feel better overall.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | February 13, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $267,911 |
| NIH project number | 5K08CA279874-02 |
| Project ID | NIH-11034097 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients in Rwanda who are receiving treatment and can provide feedback on their communication experiences.
✕Less likely to help
Patients outside of Rwanda or those not currently undergoing cancer treatment may not benefit from this research.
What this research studies
This research focuses on enhancing patient-centered communication (PCC) in cancer care in Rwanda, where many patients present with advanced disease and face significant treatment challenges. The project aims to adapt and validate a patient survey that measures the quality of communication between patients and healthcare providers. By involving patients in decision-making and providing emotional support, the research seeks to empower both patients and clinicians. The ultimate goal is to improve treatment adherence and outcomes through better communication practices.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment outcomes and patient satisfaction in Rwanda.
How similar studies have gone: Previous research has shown that enhancing patient-centered communication can significantly improve treatment adherence and outcomes in various healthcare settings.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Deboer, Rebecca — University of California, San Francisco
- Study coordinator: Deboer, Rebecca
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.